<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163039">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01786096</url>
  </required_header>
  <id_info>
    <org_study_id>SGN19A-001</org_study_id>
    <nct_id>NCT01786096</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-CD19A for Leukemia and Lymphoma</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a  phase 1, open-label, dose-escalation, multicenter study to evaluate the safety
      and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory
      B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage
      lymphoblastic lymphoma (B-LBL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month post last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month post last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response according to modified response criteria for acute myeloid leukemia (Cheson 2003) or revised response criteria for malignant lymphoma (Cheson 2007)</measure>
    <time_frame>Through 1 month post last dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Until disease progression or start of new anticancer treatment, an expected average of 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until death or study closure, an expected average of 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-CD19A and metabolites</measure>
    <time_frame>Cycles 1, 2, and 4:  predose, 30 minutes, and up to 2, 4, 8, 24, 72, 120, 168, and 336 hours post dose start; All other cycles:  predose, 30 minutes, and 168 and 336 hours post dose start; and 1 month post last dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies</measure>
    <time_frame>Predose in most cycles and 1 month post last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Burkitt Lymphoma</condition>
  <condition>Precursor B-cell Lymphoblastic Leukemia-Lymphoma</condition>
  <arm_group>
    <arm_group_label>SGN-CD19A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-CD19A</intervention_name>
    <description>SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range:  0.3-6 mg/kg</description>
    <arm_group_label>SGN-CD19A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients must be relapsed or refractory to at least 1 prior multi-agent
             systemic therapy.  Pediatric patients must be relapsed or refractory to at least 2
             prior multi-agent systemic therapies.  Patients with acute lymphoblastic leukemia who
             are Philadelphia chromosome-positive must have failed a second generation tyrosine
             kinase inhibitor.

          -  Eastern Cooperative Oncology Group status of 2 or lower

          -  Pathologically confirmed diagnosis of B-lineage acute lymphoblastic leukemia, Burkitt
             leukemia or lymphoma, or B-lineage lymphoblastic lymphoma

          -  Measurable disease

        Exclusion Criteria:

        -Allogeneic stem cell transplant  within 60 days, active acute or chronic
        graft-versus-host disease (GvHD), or receiving immunosuppressive therapy as treatment for
        GvHD
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Albertson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terri Lowe</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Biggers</last_name>
      <phone>205-975-2944</phone>
      <email>sbiggers@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Uma Borate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham / Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Adams</last_name>
      <phone>205-638-2984</phone>
      <email>jadams@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Pressey, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela McClure</last_name>
      <phone>480-301-4963</phone>
      <email>mcclure.pamela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Raoul Tibes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Brophy</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>89448</phone_ext>
      <email>brbrophy@coh.org</email>
    </contact>
    <investigator>
      <last_name>Robert Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayo Clinic Clinical Trials ReferralOffice</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>James Foran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Flanary</last_name>
      <phone>727-767-6466</phone>
      <email>Jennifer.Flanary@allkids.org</email>
    </contact>
    <investigator>
      <last_name>Gregory Hale, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Borase</last_name>
      <phone>813-745-2591</phone>
      <email>megan.borase@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Bijal Shah, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta / Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Schink</last_name>
      <phone>404-785-1645</phone>
      <email>Melissa.schink@choa.org</email>
    </contact>
    <investigator>
      <last_name>Todd Cooper, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Burke</last_name>
      <phone>617-643-5126</phone>
      <email>MBURKE19@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Amir Fathi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Hall</last_name>
      <phone>617-632-6829</phone>
      <email>HilaryN_Hall@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Lewis Silverman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie-Ann Sammott</last_name>
      <phone>617-632-6363</phone>
      <email>Stacie-AnnS_Sammott@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Daniel DeAngelo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Willard</last_name>
      <email>willarde@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Tanya Trippett, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Blank</last_name>
      <phone>513-803-3255</phone>
      <email>Courtney.Blank@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Maureen O'Brien, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burkitt Lymphoma</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>B-Lineage Acute Lymphoblastic Leukemia</keyword>
  <keyword>B-Lineage Lymphoblastic Lymphoma</keyword>
  <keyword>Burkitt Leukemia</keyword>
  <keyword>Monomethylauristatin F</keyword>
  <keyword>Antigens, CD19</keyword>
  <keyword>Drug Therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
